Αρχειοθήκη ιστολογίου

Τρίτη 12 Απριλίου 2022

Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice?

alwin shared this article with you from Inoreader
Via Oncology
CONCLUSIONS: patients who were progressive on P+ET could still benefit from a subsequent ET. In patients who experienced a good efficacy from prior ET, without visceral metastatic sites, HT seems the most suitable option, when compared to CT, also in terms of safety.PMID:34875670 | DOI:10.1159/000521252 (Source: Oncology)
View on the web

Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society® (ARS) Appropriate Use Criteria (AUC): Expert Panel on Radiation Oncology - Head and Neck Cancer:

alwin shared this article with you from Inoreader

1-s2.0-S0360301622X00035-cov150h.gif

Publication date: Available online 8 April 2022

Source: International Journal of Radiation Oncology*Biology*Physics

Author(s): Matthew C. Ward, Shlomo A. Koyfman, Richard L. Bakst, Danielle N. Margalit, Beth M. Beadle, Jonathan J. Beitler, Steven Shih-Wei Chang, Jay S. Cooper, Thomas J. Galloway, John A. Ridge, Jared R. Robbins, Assuntina G. Sacco, C. Jillian Tsai, Sue S. Yom, Farzan Siddiqui

View on the web

Status of IDH mutations in chondrosarcoma of the jaws

alwin shared this article with you from Inoreader
The aim was to analyse the relationship between mutations of the isocitrate dehydrogenase gene (IDH) and clinical characteristics of chondrosarcoma of the jaw in order to provide new information on its molecular pathology. Tissue samples were collected from 25 patients diagnosed with chondrosarcoma of the jaw. IDH mutations were detected through polymerase chain reaction and direct sequencing. Clinicopathological data were analysed retrospectively. The study included 14 female and 11 male patients; the median patient age was 38 years. (Source: International Journal of Oral and Maxillofacial Surgery)
View on the web

Randomized Trial of Conventional- vs Conventional plus Fluciclovine (18F) PET/CT-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer: Volumetric and Patient-Reported Toxicity Analyses

alwin shared this article with you from Inoreader

1-s2.0-S0360301622X00035-cov150h.gif

Publication date: Available online 11 April 2022

Source: International Journal of Radiation Oncology*Biology*Physics

Author(s): Vishal R Dhere, David M Schuster, Subir Goyal, Eduard Schreibmann, Bruce W Hershatter, Peter J Rossi, Joseph W Shelton, Pretesh R Patel, Ashesh B Jani

View on the web

TCTAP C-175 Valve-In-Valve Transcatheter Aortic Valve Replacement in a Patient With Severe Left Ventricular Systolic Dysfunction in Previous Bentall Procedure

alwin shared this article with you from Inoreader

1-s2.0-S0735109722X0003X-cov150h.gif

Publication date: 19 April 2022

Source: Journal of the American College of Cardiology, Volume 79, Issue 15, Supplement

Author(s): Satej Janorkar, Sachin Shirke, Prashant Mishra, Nilesh Juvekar

View on the web

TCTAP C-176 Trans Catheter mitral Valve in Valve Replacement in a Severely Degenerated Bioprosthetic Valve

alwin shared this article with you from Inoreader

1-s2.0-S0735109722X0003X-cov150h.gif

Publication date: 19 April 2022

Source: Journal of the American College of Cardiology, Volume 79, Issue 15, Supplement

Author(s): Bhishma Chowdary Donepudi

View on the web

Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma

alwin shared this article with you from Inoreader
Via Oncology
Conclusion: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas. (Source: Oncology)
View on the web

Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia

alwin shared this article with you from Inoreader

1-s2.0-S0735109722003862-fx1.jpg

Publication date: 19 April 2022

Source: Journal of the American College of Cardiology, Volume 79, Issue 15

Author(s): Ángel Arenal, Pablo Ávila, Javier Jiménez-Candil, Luis Tercedor, David Calvo, Fernando Arribas, Javier Fernández-Portales, José Luis Merino, Antonio Hernández-Madrid, Francisco J. Fernández-Avilés, Antonio Berruezo

View on the web

Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension

alwin shared this article with you from Inoreader

1-s2.0-S073510972200434X-fx1.jpg

Publication date: 19 April 2022

Source: Journal of the American College of Cardiology, Volume 79, Issue 15

Author(s): Yu-Ping Zhou, Yun-Peng Wei, Yin-Jian Yang, Xi-Qi Xu, Tao Wu, Chao Liu, Ke-Yi Mei, Fu-Hua Peng, Hai-Ping Wang, Kai Sun, Jing-Yi Li, Hui-Fang Wang, Meng-Tao Li, Duo-Lao Wang, Qi Miao, Xin Jiang, Zhi-Cheng Jing

View on the web

Mohs Micrographic Surgery for the Treatment of Cutaneous Melanomas of the Head and Neck

alwin shared this article with you from Inoreader
Surgical excision achieving clear histologic margins remains the mainstay treatment for primary cutaneous melanoma. Tumors of the head and neck, particularly those arising in chronically sun-damaged skin, often demonstrate extensive and asymmetric subclinical extension. Over the decades, this has proven to be a significant problem for tumors arising on the head and neck, as anatomic and functional complexities of these areas have led to suboptimal surgical treatment, yielding unacceptably high rates of local recurrence and persistently positive margins with traditional wide local excision. Patients who undergo Mohs micrographic surgery may have improved survival over those who undergo wide local excision. (Source: Oral and Maxillofacial Surgery Clinics)
View on the web

Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma

alwin shared this article with you from Inoreader
Via Oncology
CONCLUSION: Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with synovial sarcoma was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for synovial sarcomas.PMID:35405680 | DOI:10.1159/000524500 (Source: Oncology)
View on the web

NeuroEMCrit – Time is Brain – Acute Ischemic Stroke Part 2: Mechanical Thrombectomy

als.fakia shared this article with you from Inoreader

Thrombectomy-2-scaled.jpg

part II of the stroke update...

EMCrit Project by NeuroEMCrit Team (Casey & Neha).

View on the web

Retrospective analysis of adjuvant radiotherapy in oral cavity or oropharyngeal cancer: Feasibility of omitting lower-neck irradiation

als.fakia shared this article with you from Inoreader

journal.pone.0266678.g002&size=inline

by Sheng-Yow Ho, Wan-Chen Kao, Sheng-Yen Hsiao, Sheng-Fu Chiu, Sung-Wei Lee, Jia-Chun Chen, Li-Tsun Shieh

Objectives

Adjuvant radiotherapy is the standard of care in locally advanced head and neck cancers. The radiation field is correlated with the surgical field in the adjuvant radiotherapy setting; therefore, tailoring the irradiation field is reasonable.

Materials and methods

We retrospectively analyzed patients with oral cavity and oropharyngeal cancers included in the cancer registry between 2015 and 2019 in the study hospital. Patients who underwent whole-neck irradiation (WNI) were compared with those who underwent lower-neck–sparing (LNS) irradiation.

Results

A total of 167 patients with oral cavity and oropharyngeal cancers were included in the study. Cancer recurrence was recorded in 33% of the patients. The rate of recurrence of oral cavity and oropharyngeal cancer at neck level IV was 8%. The 2-year incidence of level IV recurrence was lower in the WNI group than in the LNS group (2% vs. 10%; p = 0.04). The 2-year disease-free survival rates were 75% and 63% in the WNI and LNS groups, respectively (p = 0.08).

Conclusion

The rate of level IV recurrence was higher in the LNS group than in the WNI group. Trends of improvement in disease-free survival with lower-neck irradiation suggested that it is premature to consider LNS irradiation as daily practice in patients with oral cavity and oropharyngeal cancer.

View on the web